- Joined
- Feb 25, 2013
- Messages
- 45,542
- Reaction score
- 474,322
IMO, too many reports intent to politicize studies are doing a true disservice to possible future treatment of the virus.
This is a new study of announced Friday by the University of Washington --a major new study of the malaria drug President Donald Trump has praised as a possible, low-cost cure for COVID-19. If media is to be believed -- this Rx has already been deemed 100% failure. Reduced viral shedding could be a game-changer!
UW to lead national study of drug promoted by President Trump to fight coronavirus
April 24, 2020
“We don’t know if these medicines are effective and we need to know,” Johnston said. “But we also need to make sure they’re safe, and in a clinical trial we can achieve both those things.”
[..]
Earlier studies in China that found little benefit focused on extremely ill patients, but the UW project will study people with confirmed coronavirus infections who are not sick enough to be hospitalized.
The goal is to find out if early treatment could protect people from developing viral pneumonia. The researchers also want to see if people who get the drug show reduced viral shedding, which might mean they are less likely to pass the disease on to others.
The team hopes to enroll 630 patients nationwide, including 100 to 150 in the Seattle area. Participants will be randomly assigned to receive either a 10-day course of hydroxychloroquine, hydroxychloroquine plus azithromycin or a placebo. Results should be available by July.
This is a new study of announced Friday by the University of Washington --a major new study of the malaria drug President Donald Trump has praised as a possible, low-cost cure for COVID-19. If media is to be believed -- this Rx has already been deemed 100% failure. Reduced viral shedding could be a game-changer!
UW to lead national study of drug promoted by President Trump to fight coronavirus
April 24, 2020
“We don’t know if these medicines are effective and we need to know,” Johnston said. “But we also need to make sure they’re safe, and in a clinical trial we can achieve both those things.”
[..]
Earlier studies in China that found little benefit focused on extremely ill patients, but the UW project will study people with confirmed coronavirus infections who are not sick enough to be hospitalized.
The goal is to find out if early treatment could protect people from developing viral pneumonia. The researchers also want to see if people who get the drug show reduced viral shedding, which might mean they are less likely to pass the disease on to others.
The team hopes to enroll 630 patients nationwide, including 100 to 150 in the Seattle area. Participants will be randomly assigned to receive either a 10-day course of hydroxychloroquine, hydroxychloroquine plus azithromycin or a placebo. Results should be available by July.